HOME / Featured News / NEWS FROM THE FEDS
Medicare Confirms Requirement to Return Overpayments
Rate This Article:
0
In an article titled Medicare Confirms Requirement to Return Overpayments Within 60 Days, By Jed Morrison, it is reported that "on February 14, 2012, the Centers for Medicare and Medicaid Services ("CMS") published a proposed rule implementing the requirements of the Affordable Care Act requiring Medicare providers and suppliers to report and return Medicare overpayments by the later of 60 days after the date on which the overpayment was identified, or the date any corresponding cost report is due. Failure to identify, report and return the overpayment within the 60 day deadline constitutes a false claim under the False Claims Act, which subjects the provider or supplier to additional penalties under the law."

"Section 6402 of the Patient Protection and Affordable Care Act ("Affordable Care Act") establishes a new section of the Social Security Act entitled "Reporting and Returning of Overpayments." The law requires a person who has received an overpayment from Medicare or Medicaid to report and return the overpayment to the Secretary of Health and Human Services, the State, an intermediary, a carrier, or a Medicare contractor (as appropriate) and to notify such party in writing of the reason for the overpayment. Although the provisions of the statute are self implementing and thus already in effect, the proposed rule published this week (which for now applies only to Medicare Part A and Part B providers and suppliers), gives providers additional detail on the procedures for returning the overpayments, including establishing a mandatory "self-reported overpayment refund process" ("SORP")."

"In addition to when a provider objectively identifies an overpayment, the proposed rule concludes that a person has "identified" an overpayment (thus triggering the 60-day refund window) if the person has actual knowledge of the existence of the overpayment or acts in reckless disregard or deliberate ignorance of the overpayment. CMS notes that it believes that "defining 'identification' in this way gives providers and suppliers an incentive to exercise reasonable diligence to determine whether an overpayment exists. Without such a definition, some providers and suppliers might avoid performing activities to determine whether an overpayment exists, such as self audits, compliance checks, and other additional research."

There is thus an affirmative obligation on the part of all Medicare participating providers and suppliers to have procedures in place through which they can identify overpayments. In the event of an identified overpayment, CMS will want to know what those procedures are and how the provider identified the overpayment."

"If an overpayment is claims related, such as all physician services under Medicare Part B, the provider or supplier will be required to report and return the overpayment within 60 days of identification. For those providers (like hospitals) that submit costs reports, if the overpayment is one that generally would be reconciled on the cost report in the normal course of business, the provider is permitted to report and return the overpayment either 60 days after identification or on the date the cost report is due, whichever is later. CMS emphasizes that the cost report deadline is not applicable if the overpayment is such that it would not ordinarily be reconciled on a Medicare Cost Report."

"Calculation of the 60 day deadline is perhaps the most critical aspect of the rule. CMS notes that:

"in some cases, a provider or supplier may receive information concerning a potential overpayment that creates an obligation to make a reasonable inquiry to determine whether an overpayment exists. If the reasonable inquiry reveals an overpayment, the provider then has 60 days to report and return the overpayment…Failure to make a reasonable inquiry, including failure to conduct such inquiry with all deliberate speed after obtaining the information, could result in the provider knowingly retaining an overpayment…"

"CMS proposes to implement these requirements by using the existing voluntary refund process described in the Medicare Financial Management Manual. Under that currently voluntary refund process, providers and suppliers report overpayments using a form that each Medicare contractor makes available on its website. In the proposed rule, however, CMS proposes that providers and suppliers would be required to use the self-reported overpayment refund process set forth by the applicable Medicare contractor to report and return overpayments. Thus, a simple letter to the Medicare carrier enclosing a refund check will not suffice to comply with the rule."

"Providers and suppliers failing to identify, report and return overpayments within the 60 day deadline are deemed to have filed a false claim under the False Claims Act. Liability under the False Claims Act includes treble damages, plus penalties up to $11,000 per false claim. False claims also generate liability of $10,000 per claim under the Civil Monetary Penalties law, and could also result in exclusion from participation in federal healthcare programs."

 
Post A Comment
* Indicates Required Field
Comment Title:
* Comments:
Nickname:
* Validation:
Most Recent Comments
 
 
FeaturedNews
Clinical Trial Data Should Be Open for Review
Published 04/30/2012 - 3:14 p.m.  CDT

Original clinical study reports, which contain far more detail than published randomized trials, should be made available to independent researchers seeking to verify efficacy and safety claims.

In support of this argument, the history of the influenza antiviral oseltamivir (Tamiflu), which was approved by the FDA in 1999, was cited. The widespread belief in oseltamivir's efficacy, was based on a meta-analysis of 10 trials conducted by the manufacturer prior to licensure.  But the authors pointed out that the FDA, which was aware of these clinical trials, concluded that oseltamivir had not been shown to reduce complications and required a statement on the drug's label to that effect.  Moreover, oseltamivir was not given an FDA indication for prevention of spread of influenza.

To this, [authors] commented, "If FDA is right, the drug's effectiveness may be no better than aspirin or acetaminophen.'"
...Read More
HR 329 in need of Co Sponsors
Published 04/30/2012 - 11:11 a.m.  CDT

Representative Bob Filner recently introduced the Chiropractic Care to All Veterans Act (H.R. 329). The bill would require the Veterans Administration (VA) to have a chiropractic physician on staff at all major VA medical facilities by 2014. You too can help ensure chiropractic care is available to those who have placed their lives in service to our country. H.R. 329 is in need of cosponsors to assist its likelihood of passage.

CLICK HERE to urge your legislators to cosponsor the bill.
...Read More
Court Sides with Generic-Drug Makers
Published 04/25/2012 - 6:33 a.m.  CDT

In a unanimous decision, the Supreme Court ruled that generic drugmaker Caraco Pharmaceutical Laboratories can sue Novo Nordisk for what Caraco says are exaggerated descriptions of the scope of patents Novo Nordisk holds on a diabetes drug.

A group of Democratic senators has introduced a bill that would allow people to sue generic drugmakers over failing to update their drug labels to include all known risks. The bill is meant to counter last year's Supreme Court decision in a generic drug dispute.
...Read More
Reader Login
Username:
Password:
 Save Login?
Free Sign-up
Forgot Password?
Reader Control Panel

The TCA Web sites will be under going change in the next few weeks.  Please bear with us while we complete some improvements.

Original clinical study reports, which contain far more detail than published randomized trials, should be made available to independent researchers seeking to verify efficacy and safety claims.

In support of this argument, the history of the influenza antiviral oseltamivir (Tamiflu), which was approved by the FDA in 1999, was cited. The widespread belief in oseltamivir's efficacy, was based on a meta-analysis of 10 trials conducted by the manufacturer prior to licensure.  But the authors pointed out that the FDA, which was aware of these clinical trials, concluded that oseltamivir had not been shown to reduce complications and required a statement on the drug's label to that effect.  Moreover, oseltamivir was not given an FDA indication for prevention of spread of influenza.

To this, [authors] commented, "If FDA is right, the drug's effectiveness may be no better than aspirin or acetaminophen.'"

The Kilgore College Small Business Development Center (SBDC) will sponsor an educational seminar for medical office staff, including office managers and billing staff, entitled Basic Workers’ Compensation for Medical Office Staff on Wednesday, May 2, 2012.

Representative Bob Filner recently introduced the Chiropractic Care to All Veterans Act (H.R. 329). The bill would require the Veterans Administration (VA) to have a chiropractic physician on staff at all major VA medical facilities by 2014. You too can help ensure chiropractic care is available to those who have placed their lives in service to our country. H.R. 329 is in need of cosponsors to assist its likelihood of passage.

CLICK HERE to urge your legislators to cosponsor the bill.

An $8 billion Medicare demonstration program is poorly designed and should be cancelled, the nonpartisan Government Accountability Office (GAO) said. The program is designed to reward the highest-quality Medicare Advantage plans, but instead pays out most of its award money to mediocre plans, according to a report.


Ethiopia and Kenya Trips.  Have you ever wanted to provide chiropractic care in another country and give back to those in need?

Dr. Teresa Jones has been volunteering on mission trips to Africa for 4 years and is reaching out to the District 5 for help this year. There are two chances to participate, both in July 2012 and if you are interested please RSVP to frontdesk@wholehealth-care.com to let her know you area interested!


The Patient-Centered Outcomes Research Initiative (PCORI), established by the 2010 Patient Protection and Affordable Care Act, has set five priorities as the group's research agenda for the coming years, with the overall goal of advancing clinical effectiveness research. …. the priorities [are] as follows...

Girls who face multiple social stressors at home as toddlers are more likely to be obese by age 5, researchers found.

Nonpharmacologic pain management appears to be safe for mother and baby, although there is limited published evidence to explain its efficacy, according to a Cochrane Review.

There is more data to support the ef?cacy of pharmacologic pain management, such as epidurals and opioids, but these methods lead to more adverse effects.  This reports reports upon some of these
Regulators on both sides of the Atlantic were slow to inform patients and their doctors about problems with metal-on-metal hip implants and relied on industry officials and consultants in crafting their responses.

Complications included high failure rates and possible systemic effects from elevated metal ion levels in the blood.  An advisory has been issued to surgeons, telling them that patients who have received metal-on-metal implants should have annual checkups for life. The evaluations should include testing for metal ions in the blood as well as for clinical symptoms of device failure.